Press Release

Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510

REDWOOD CITY, CA – November 4, 2019 – Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced an agreement with…

Read more

Press Release

Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

REDWOOD CITY, CA – October 22, 2019 – Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced that preclinical in…

Read more

Publication / Presentation

Press Release

Revolution Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

REDWOOD CITY, CA – September 17, 2019 – REVOLUTION Medicines, Inc., a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced dosing of the…

Read more

Publication / Presentation

News

Revolution Medicines snags $100M to attack RAS-mutated cancers

Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. These include a program targeting KRAS mutations, which were previously considered undruggable.…

Read more